Here are three points:
1. ProteiOS is composed of minimally manipulated allogenic bone marrow.
2. It contains angiogenic, mitogenic and osteoinductive proteins and the highest amount of non-recombinant BMP-2.
3. The device may be used with the surgeon’s choice of FDA-approved scaffold or matrix.
“In addition to the significant array of growth factors in the product, it has easy storage and prep and offers significant cost and time savings over rhBMP-2 and stem cell products,” said Scott Cadotte, vice president of sales and marketing, Biologica Technologies.
More articles on devices:
FDA approves Mobi-C disc labeling update; includes 5-year study data: 6 things to know
Exactech launches Acapella One Cervical Spacer System: 5 key points
Life Spine releases devices for expandable lateral interbody fusions: 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
